Counsel Health enters the GLP-1 market with physician-led, AI-supported obesity care
Counsel Health is pushing into one of the most crowded corners of digital health with a weight management program built around GLP-1 therapy, on-demand physician access and AI-based monitoring. The program will be available through Counsel Health and Eli Lilly’s LillyDirect digital pharmacy, tying a primary care model to a direct-to-consumer medication channel at a moment when obesity treatment is drawing intense demand and scrutiny.
The offering is designed for members in 44 states and centers on a simple clinical promise: patients should not have to choose between getting a prescription and getting real follow-up care. After a digital intake, Counsel physicians determine eligibility and create individualized treatment plans. Physicians can prescribe Wegovy, Zepbound and Foundayo, and members can reach board-certified clinicians on demand with questions about side effects, dosing or treatment progress.
A single prescription rarely resolves the burdens of obesity care.
Why continuity matters more in obesity treatment than in a pharmacy checkout
The clinical logic behind Counsel’s model is easy to see. Obesity is not a static diagnosis, and GLP-1 treatment is not a one-time event. Dose escalation, gastrointestinal side effects, adherence problems, missed refills and changes in cardiometabolic status can alter the course of care over weeks and months. A system that only handles the initial prescription can leave patients isolated exactly when they most need guidance.
Counsel is framing its platform as an answer to that gap. Muthu Alagappan, M.D., the company’s CEO and founder, said weight-loss medication has become more available while ongoing, personalized care has not kept pace. He described fragmented systems as a barrier for patients trying to manage chronic conditions, including weight management. The company’s pitch rests on the idea that medication access and longitudinal oversight should function as one clinical pathway rather than two disconnected transactions.
That approach carries particular weight in obesity medicine because side effects and treatment persistence often determine whether therapy succeeds in practice. If a patient stops a drug during dose escalation because no clinician is readily available to troubleshoot nausea, constipation or questions about dosing, the value of the medication erodes quickly. Counsel is betting that fast access to physicians, backed by AI check-ins, can reduce those drop-offs.
AI check-ins are positioned as support, not replacement, for clinical judgment
Counsel says its medical AI proactively checks in on progress and side effects, while members can also ask questions at any time or connect directly with a physician, typically within minutes. The company is presenting AI as a triage and continuity layer rather than a substitute for medical decision-making. In practice, that means the technology is meant to catch concerns early, prompt follow-up and make clinician access feel immediate when symptoms or dosing questions arise.
The platform’s AI tools are included at no extra cost. Counsel also says its AI-native care model lowers the cost of access compared with traditional weight management programs, with two pricing options: Counsel Signature offers unlimited access to care for $300 per year, while pay-as-you-go visits are available for $29 per physician visit.
Those prices matter in a market where affordability often determines whether patients stay engaged. For chronic weight management, recurring touchpoints are not cosmetic add-ons; they are part of the treatment architecture. If the follow-up structure is too expensive or too cumbersome, persistence tends to suffer, and the therapeutic benefit of the medication can be lost before the patient reaches a stable dose or a meaningful response.
LillyDirect gives the program a direct-to-consumer channel with national reach
The partnership with Eli Lilly places the program inside LillyDirect, the company’s direct-to-consumer digital pharmacy platform. That arrangement gives Counsel a distribution pathway that links prescribing, patient education and medication access under one ecosystem. It also places the program in a broader commercial environment where large pharmaceutical companies, digital pharmacies and AI-enabled care models are competing to shape how obesity treatment is delivered.
Counsel’s move lands as use of GLP-1 medications for weight loss continues to expand. The company cites a rise in U.S. adults taking these medications for weight loss to 11% in 2026, up from 3% in 2024. In the same breath, Counsel points to a persistence problem: only 32% of GLP-1 users remain on therapy by the end of year one, dropping to 15% by year two. Those figures explain why companies in this space are increasingly focused on engagement, follow-up and chronic care infrastructure rather than medication access alone.
The persistence numbers are clinically important because they suggest the main challenge is not simply whether patients can obtain the drug. The harder problem is whether a care model can keep patients supported long enough for the medication to do its work safely and consistently. In obesity treatment, discontinuation can stem from tolerability, cost, uncertainty about results or a lack of responsive clinical support. Any platform that aims to improve outcomes has to address all four.
Primary care integration could widen the program’s clinical scope
Counsel says membership includes comprehensive primary care, including support for chronic conditions. That broader scope may be one of the program’s most clinically relevant features, because obesity rarely exists alone. Blood pressure, glycemic control, sleep disorders and other chronic issues often shape medication choice, safety monitoring and overall treatment goals. By embedding obesity care in a primary care model, Counsel is signaling that weight management should be treated as part of a patient’s broader health history rather than as a standalone commercial service.
The company’s framing also reflects a larger shift in digital health: the most durable programs are the ones that can manage both episodic questions and longitudinal disease burden. Patients need help when they start therapy, when doses change, when side effects appear and when progress stalls. A care model that can meet those moments without forcing patients into a new workflow each time may be better aligned with the realities of chronic treatment.
For now, Counsel’s program is a market entry with a clear clinical thesis and a commercial ally already active in the obesity space. The central question is whether AI-supported access, physician oversight and direct pharmacy linkage can improve persistence and quality in day-to-day use. The article does not provide outcomes data, so the program’s real-world effect on adherence, safety or weight loss remains unproven.